Clinical Breakthrough: ANVISA Approves Human Trials for Spinal Cord Repair

In February 2026, the regulatory body ANVISA granted permission to begin Phase I human clinical trials for spinal cord regeneration. This study, led by Tatyana Coelho de Sampaio, challenges the long-standing medical belief that nerve connections cannot be restored after trauma. By utilizing decades of research on laminin, the team aims to stimulate neuron growth in human subjects for the first time. This transition from lab to clinic marks a pivotal moment in neuroscience, offering a potential life-changing solution for patients with spinal injuries.

Source: Amul Info